Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 18;35(11):239.
doi: 10.1007/s11095-018-2514-2.

Progress in Inherited Retinal Disease Drug Discovery and Development: A Foundation's Perspective

Benjamin Yerxa  1
Affiliations
Review

Progress in Inherited Retinal Disease Drug Discovery and Development: A Foundation's Perspective

Benjamin Yerxa. Pharm Res. .

Abstract

Ophthalmic drug discovery and development has enjoyed a recent renaissance, with a major shift away from reformulating old systemic drugs for ocular use to de novo discovery of drugs for specific ocular disease targets. This shift, coupled with a revolution in molecular biology and genetic sequencing, has uncovered an unprecedented number and variety of novel targets for therapeutic intervention in eye disease. With such a treasure chest of new science to pursue, it also creates a new challenge for translating the lab-based discoveries through the translational "valley of death" into full scale industry-led development of new, approved therapeutics to treat eye disease. This is in fact a daunting task, as the cost of drug development continues to increase and many of the new therapeutic targets are based on smaller, orphan diseases with very high unmet medical needs. This perspective focuses on the role of a nonprofit foundation, The Foundation Fighting Blindness, in fueling and supporting the advancement of new therapies for blinding inherited retinal degenerative diseases into approved therapeutics. The new collaborative model is changing the way breakthrough drugs are coming to market for patients, and innovative funding models are required to match the innovative science.

Keywords: inherited retinal degenerative disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Cremers FPM, Boon CJF, Bujakowska K, Zeitz C. Special issue introduction: Inherited retinal disease: novel candidate genes, genotype-phenotype correlations, and inheritance models. Genes. 2018;9:215. doi: 10.3390/genes9040215. - DOI - PMC - PubMed
    1. Arai AK, Maeda A, Hirami Y, Ishigami C, Kosuge S, Mandai M, et al. Retinitis pigmentosa with EYS mutations is the most prevalent inherited retinal dystrophy in Japanese populations. J Ophthalmol. 2015;9:819760. - PMC - PubMed
    1. Mardis ER. A decade’s perspective on DNA sequencing technology. Nature. 2011;470:198–203. doi: 10.1038/nature09796. - DOI - PubMed
    1. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, et al. Effect of oral valproic acid vs placebo for vision loss in patients with autosomal dominant retinitis pigmentosa. JAMA Ophthalmol. 2018;136:849–856. doi: 10.1001/jamaophthalmol.2018.1171. - DOI - PMC - PubMed
    1. Birch DG, Locke KG, Wen Y, Locke KI, Hoffman DR, Hood DC. Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with x-linked retinitis pigmentosa. JAMA Ophthalmol. 2013;131(9):1143–1150. doi: 10.1001/jamaophthalmol.2013.4160. - DOI - PMC - PubMed